Literature DB >> 26037299

Resveratrol Protects Against Pathological Preterm Birth by Suppression of Macrophage-Mediated Inflammation.

Hitomi Furuya1, Ayumi Taguchi1, Kei Kawana2, Aki Yamashita1, Eri Inoue1, Mitsuyo Yoshida1, Hiroe Nakamura1, Asaha Fujimoto1, Tomoko Inoue1, Masakazu Sato1, Haruka Nishida1, Kazunori Nagasaka1, Katsuyuki Adachi1, Mari Hoya1, Takeshi Nagamatsu1, Osamu Wada-Hiraike1, Takahiro Yamashita1, Yutaka Osuga1, Tomoyuki Fujii1.   

Abstract

Inflammatory cytokines play a major role in spontaneous preterm birth. Resveratrol has strong anti-inflammatory effects, but its effect on preterm birth in vivo is unknown. We investigated whether resveratrol protects against preterm birth in the lipopolysaccharide (LPS)-induced preterm mouse model. Twelve-day-old pregnant mice were fed 20 to 40 mg/kg resveratrol daily. On day 15, 10 μg of LPS was injected into uterine cervices. Resveratrol administration significantly decreased the rate of preterm birth. Resveratrol administration abolished LPS-induced elevation of tumor necrosis factor α (TNF-α) and interleukin (IL) 1β but not IL-6 levels. The TNF-α messenger RNA levels were decreased in the cervices of resveratrol-administered mice compared with controls. Resveratrol treatment suppressed the elevation in TNF-α and IL-1β levels in LPS-exposed peritoneal macrophages. Further resveratrol treatment eradicated the proinflammatory cytokine-mediated elevation in cyclooxygenase 2 (COX-2) in peritoneal macrophages. Resveratrol may protect against pathological preterm birth by suppression of elevated proinflammatory cytokines and consequent elevation of COX-2 in macrophages.
© The Author(s) 2015.

Entities:  

Keywords:  COX-2; LPS-induced preterm birth; anti-inflammatory effect; peritoneal macrophage; resveratrol

Mesh:

Substances:

Year:  2015        PMID: 26037299     DOI: 10.1177/1933719115589413

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  7 in total

1.  Resveratrol protects from lipopolysaccharide-induced inflammation in the uterus and prevents experimental preterm birth.

Authors:  María Victoria Bariani; Fernando Correa; Emma Leishman; Ana Paula Domínguez Rubio; Andreína Arias; Aníbal Stern; Heather B Bradshaw; Ana María Franchi
Journal:  Mol Hum Reprod       Date:  2017-08-01       Impact factor: 4.025

2.  Prophylactic administration of human amniotic fluid stem cells suppresses inflammation-induced preterm birth via macrophage polarization.

Authors:  Yushi Abe; Daigo Ochiai; Seiji Kanzaki; Yu Sato; Toshimitsu Otani; Satoru Ikenoue; Yoshifumi Kasuga; Mamoru Tanaka
Journal:  Mol Cell Biochem       Date:  2022-07-10       Impact factor: 3.396

3.  Advanced glycation end products and lipopolysaccharides stimulate interleukin-6 secretion via the RAGE/TLR4-NF-κB-ROS pathways and resveratrol attenuates these inflammatory responses in mouse macrophages.

Authors:  Ayaka Ohtsu; Yui Shibutani; Kotomi Seno; Hisataka Iwata; Takehito Kuwayama; Koumei Shirasuna
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

4.  A Role for the Inflammasome in Spontaneous Labor at Term with Acute Histologic Chorioamnionitis.

Authors:  Nardhy Gomez-Lopez; Roberto Romero; Yi Xu; Olesya Plazyo; Ronald Unkel; Nandor Gabor Than; Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Zhong Dong; Adi L Tarca; Vikki M Abrahams; Lami Yeo; Sonia S Hassan
Journal:  Reprod Sci       Date:  2016-11-16       Impact factor: 3.060

5.  ASK1 promotes uterine inflammation leading to pathological preterm birth.

Authors:  Midori Yoshikawa; Takayuki Iriyama; Kensuke Suzuki; Seisuke Sayama; Tetsushi Tsuruga; Keiichi Kumasawa; Takeshi Nagamatsu; Kengo Homma; Isao Naguro; Yutaka Osuga; Hidenori Ichijo; Tomoyuki Fujii
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

6.  Preterm Birth Therapies to Target Inflammation.

Authors:  Ioannis Pavlidis; Sarah J Stock
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

7.  Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.

Authors:  Valeria Garcia-Flores; Roberto Romero; Derek Miller; Yi Xu; Bogdan Done; Chharitha Veerapaneni; Yaozhu Leng; Marcia Arenas-Hernandez; Nabila Khan; Bogdan Panaitescu; Sonia S Hassan; Luis Marat Alvarez-Salas; Nardhy Gomez-Lopez
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.